相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response
Laura Valerio et al.
ENDOCRINE-RELATED CANCER (2020)
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model
Paul Tappenden et al.
HEALTH TECHNOLOGY ASSESSMENT (2019)
Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives
Lucieli Ceolin et al.
ENDOCRINE-RELATED CANCER (2019)
Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis
Pierpaolo Trimboli et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
Ira L. Kraft et al.
CLINICAL CANCER RESEARCH (2018)
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study
Alain Ravaud et al.
EUROPEAN JOURNAL OF CANCER (2017)
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
Jaume Capdevila et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma
Yasuhiro Ito et al.
THYROID (2017)
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
M. Schlumberger et al.
ANNALS OF ONCOLOGY (2017)
SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY
Keita Uchino et al.
ENDOCRINE PRACTICE (2017)
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Martin Schlumberger et al.
CLINICAL CANCER RESEARCH (2016)
New drugs for medullary thyroid cancer: new promises?
Christine Spitzweg et al.
ENDOCRINE-RELATED CANCER (2016)
Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients
Vera Tiedje et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Evolving molecularly targeted therapies for advanced-stage thyroid cancers
Keith C. Bible et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis
Luciana Audi de Castroneves et al.
THYROID (2016)
Management of advanced medullary thyroid cancer
Julien Hadoux et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
Sun Min Lim et al.
EUROPEAN JOURNAL OF CANCER (2015)
Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis
E. N. Klein Hesselink et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
R. A. Werner et al.
MEDICINE (2015)
Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results from a French Cohort
Cecile N. Chougnet et al.
THYROID (2015)
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
Samuel A. Wells et al.
THYROID (2015)
Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population
Mustafa Benekli et al.
ONCOTARGETS AND THERAPY (2015)
Treatment of Advanced Thyroid Cancer With Axitinib: Phase 2 Study With Pharmacokinetic/Pharmacodynamic and Quality-of-Life Assessments
Laura D. Locati et al.
CANCER (2014)
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network
Marie-Helene Massicotte et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H
Keith C. Bible et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sorafenib in metastatic thyroid cancer
Jaume Capdevila et al.
ENDOCRINE-RELATED CANCER (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
Merina Ahmed et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Rapid Response to Sorafenib in Metastatic Medullary Thyroid Carcinoma
K. Frank-Raue et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2011)
Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies
David S. Hong et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
Laurie L. Carr et al.
CLINICAL CANCER RESEARCH (2010)
The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors
Lei Ye et al.
ENDOCRINE REVIEWS (2010)
Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Bruce G. Robinson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Elaine T. Lam et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
Martin J. Schlumberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
RET genetic screening in patients with medullary thyroid cancer and their relatives:: Experience with 807 individuals at one center
Rossella Elisei et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma
J. W. B. de Groot et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma
Karin Frank-Raue et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R
DJ Gross et al.
ENDOCRINE-RELATED CANCER (2006)
分享论文
